Inotuzumab ozogamicin and Insulin aspart, recombinant Subcutaneous
Determining the interaction of Inotuzumab ozogamicin and Insulin aspart, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: inotuzumab ozogamicin
Brand name: Besponsa
Synonyms: Inotuzumab Ozogamicin
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Inotuzumab ozogamicin-Insulin degludec
- Inotuzumab ozogamicin-Insulin Degludec (U-100) Prefilled Pens
- Inotuzumab ozogamicin-Insulin Degludec (U-100) Vials
- Inotuzumab ozogamicin-Insulin Degludec (U-200) Prefilled Pens
- Inotuzumab ozogamicin-Insulin degludec and liraglutide
- Inotuzumab ozogamicin-Insulin degludec and liraglutide Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Inotuzumab ozogamicin Intravenous
- Insulin aspart, recombinant Subcutaneous-Inova
- Insulin aspart, recombinant Subcutaneous-Inova 4/1 topical
- Insulin aspart, recombinant Subcutaneous-Inova 8/2 topical
- Insulin aspart, recombinant Subcutaneous-Inova ACT
- Insulin aspart, recombinant Subcutaneous-Inrebic